Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 5/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 8/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20695457 | 0.74 | HSD11B1 (0.51) | MGLLNAMPTCYP11B1CYP11B2CD274 | |
| SCHEMBL20695210 | 0.72 | MAPK1 (0.50) | CRBNDDB1 | |
| SCHEMBL30620955 | 0.70 | CYP11B1 (0.38) | MGLLCRBNCYP11B1CYP11B2CD274 | |
| SCHEMBL20695340 | 0.69 | BRD4 (0.50) | MGLLCRBNDDB1 | |
| SCHEMBL20695455 | 0.68 | MAPT (0.55) | — | |
| SCHEMBL20695504 | 0.68 | HTT (0.54) | CRBN | |
| SCHEMBL20695172 | 0.68 | HRH4 (0.52) | — | |
| SCHEMBL20695238 | 0.68 | CRBN (0.39) | MGLLNAMPTCRBNDDB1 | |
| SCHEMBL20695092 | 0.68 | RAB9A (0.43) | — | |
| SCHEMBL20695447 | 0.68 | MGLL (0.39) | MGLLCD274PDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10610520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-07 | — | — | US | disclosed |
| US-20190125728-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-02 | — | — | US | disclosed |
| US-20190125728-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-02 | — | — | US | disclosed |
| EP-3438109-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-02-06 | — | — | EP | disclosed |
| EP-3438109-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125728-A1 | HETEROCYCLIC COMPOUND | MAG, HTT, ACHE | MAOA 198/4885MAOB 234/4885MGLL 138/4885 |
| US-10610520-B2 | Heterocyclic compound | MAG, HTT, ACHE | MAOA 198/4885MAOB 234/4885MGLL 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.